Clinical trials: Intravenous Injections, active
Ischemic Stroke, Acute
Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)
Shuxuening injection is a multi-target neuroprotective agent, it is expected to play a neuroprotective role on the basis of intravenous thrombolysis therapy.
- Trial name
- NCT06157502
- Testing
- Shuxuening Injection
- Where
- 82 sites in China
- Volunteers
- 1,380 people
- Sponsor
- Beijing Tiantan Hospital
Laparoscopic Appendectomy
Comparing Pain Relief Between Two Methods of Freezing Injections in Children Having Their Appendix Removed
Laparoscopic appendectomies are the most common emergency surgeries performed in children. Despite being considered minimally invasive surgeries, they can result in substantial postoperative pain and 2 of 3 patients require…
- Trial name
- NCT06945263
- Testing
- Rectus Sheath Block, Local Anesthetic at the Umbilical Port Site, Intravenous Dexamethasone
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- University of British Columbia
Crohn Disease, Resection Margins
Cellvizio to Evaluate Margins in Crohn's Ileal Disease
Crohn disease is an inflammatory bowel disease. A surgical procedure is required in about 80% of cases. Surgery doesn't cure from Crohn's disease but the type of surgery remains important as there are several intraoperative risk…
- Conditions
- Crohn Disease, Resection Margins, Recurrence
- Trial name
- CELLVICROHN (NCT05805020)
- Testing
- cellvizio
- Where
- France
- Volunteers
- 41 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Acute Ischemic Stroke
Fructose for Acute Ischemic Stroke
This is a single-center, prospective, randomized, open-label, blinded-endpoint exploratory clinical study enrolling 46 patients with acute ischemic stroke.
- Trial name
- FRUCTOSE-AIS (NCT07626541)
- Testing
- 10% Fructose Injection
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Ji Xunming,MD,PhD
Autism Spectrum Disorder
A Study of Mesenchymal Stem Cell in the Treatment of Autism Spectrum Disorder
This clinical trial aims to evaluate the safety and preliminary efficacy of intravenous administration of human bone marrow-derived mesenchymal stem cells (hBMMSCs) in patients with autism spectrum disorder (ASD).
- Trial name
- ASD (NCT07177677)
- Testing
- hBMMSC
- Volunteers
- 42 people
- Sponsor
- Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
Osteoporosis in Post-menopausal Women, Osteoporosis
Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture
The primary objective of this study is to evaluate the safety and tolerability of human umbilical cord-derived mesenchymal stem cells for injection (HMM910 ) in postmenopausal women with osteoporosis who are at high risk of…
- Trial name
- NCT06949137
- Testing
- Human Umbilical Cord-derived Mesenchymal stem cell
- Where
- China
- Volunteers
- 9 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Chronic Liver Disease
In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop
Control group : LAENNEC subcutaneous injection (4 ml) Experimental group : LAENNEC intravenous injection (10 ml)
- Trial name
- NCT06493799
- Testing
- LAENNEC (Human Placenta Hydrolysate) IV, LAENNEC (Human Placenta Hydrolysate) SC
- Where
- South Korea
- Volunteers
- 226 people
- Sponsor
- Green Cross Wellbeing
Rheumatoid Arthritis
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion and Intra-Articular Injection for RA
This trial will study the safety and efficacy of intravenous infusion and intra-articular injection of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of Rheumatoid Arthritis
- Trial name
- NCT05003934
- Testing
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells
- Where
- 2 sites in United States, Greece
- Volunteers
- 20 people
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
Duchenne Muscular Dystrophy (DMD)
Evaluation of the Safety, Tolerability, and Efficacy of LE051 in Patients With Duchenne Muscular Dystrophy
The purpose of this study is to evaluate the safety, tolerability, and efficacy of LE051 intravenous therapy in DMD patients treated with exon 51 skipping therapy.
- Trial name
- NCT06900049
- Testing
- LE051
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Glioblastoma
Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma
The main objective of this clinical study is to evaluate the safety and tolerability of NK-92/5.28.z and to determine the maximum tolerated dose or maximum feasible dose (MFD).
- Trial name
- CAR2BRAIN (NCT03383978)
- Testing
- NK-92/5.28.z, Ezabenlimab
- Where
- 5 sites in Germany
- Volunteers
- 42 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Preventing Propofol Pain on Injection
Comparative Efficacy of IV Parecoxib vs Lidocaine in Reducing Propofol Injection Pain
Propofol is the most popular IV anaesthetic agent used for induction, however one of its known side effects is causing pain on injection, the gold standard method in preventing this pain is using lidocaine prior to injecting…
- Trial name
- NCT07116304
- Testing
- Lidocaine, a local anaesthetic., Parecoxib 40mg
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Oman Medical Speciality Board
Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric…
- Trial name
- NCT07043400
- Testing
- Subcutaneous Tislelizumab, Intravenous Tislelizumab, Cisplatin
- Where
- 95 sites in United States, Argentina and 14 more
- Volunteers
- 351 people
- Sponsor
- BeOne Medicines
Metachromatic Leukodystrophy (MLD)
Direct Lentiviral Injection Gene Therapy for MLD
This is a Phase I/II clinical trial of gene therapy for treating Metachromatic leukodystrophy (MLD) using a safety and efficacy improved self-inactivating lentiviral vector TYF-ARSA to functionally correct the genetic defect.
- Trial name
- NCT03725670
- Testing
- Intrathecal and intravenous LV gene therapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Pompe Disease Infantile-Onset
Evaluation of the Safety and Efficacy of Infantile-onset Pompe Disease Gene Therapy Drug
This study is being conducted to evaluate the safety and effectiveness of GC301 adeno-associated virus vector expressing codon-optimized human acid alpha-glucosidase (GAA) as potential gene therapy for Pompe disease.
- Trial name
- NCT05793307
- Testing
- GC301
- Where
- 5 sites in China
- Volunteers
- 16 people
- Sponsor
- GeneCradle Inc
Major Depressive Disorder, Healthy Volunteer
First-In-Human (FIH), Single Ascending Dose (SAD) Study and Multiple Ascending Dose (MAD) Study of SP-101 Injection
The goal of this First-In-Human (FIH) trial is to learn about safety, tolerability and pharmacokinetics of single and multiple ascending doses of SP-101 in healthy adult volunteers.
- Trial name
- NCT07334249
- Testing
- SP-101 injection
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.
Advanced Malignant Solid Tumor
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of VG2025 Intravenous Injection in Subjects With Advanced Solid Tumors
VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. This Phase I study will be conducted in herpes simplex virus (HSV) -seropositive subjects with advanced malignant solid tumors that are refractory to…
- Trial name
- NCT07682870
- Testing
- Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Virogin Biotech Ltd.
Acute Ischemic Stroke, rhTNK-tPA
Observational Study to Assess the Safety of rhTNK-tPA (Mingfule®) vs. Rt-PA (Actilyse®) in Treating Acute Ischemic Stroke
This is a multicenter, prospective, non-randomized, post-marketing safety surveillance cohort study with rt-PA (Actilyse®) as the control.
- Trial name
- NCT07519889
- Testing
- rhTNK-tPA, rt-PA
- Volunteers
- 4,500 people
- Sponsor
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Primary Intraocular Lymphoma
ZR-MTX for PIOL Phase II Trial
This is a prospective single-arm phase II study, with the purpose of evaluating the efficiency of ZR-MTX regimen (Rituximab, Zanubrutinib and methotrexate) combined with intravitreal methotrexate, then followed by minimal…
- Trial name
- ZR-MTX (NCT06973811)
- Testing
- Methotrexate, Rituximab (R), Zanubrutinib
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Peking Union Medical College Hospital
Acute Ischemic Stroke
Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study designed to evaluate the efficacy of recombinant human tissue-type plasminogen activator variant (rhTNK-tPA) (0.25 mg/kg, maximum dose…
- Trial name
- TRACE-LATE (NCT07201688)
- Testing
- rhTNK-tPA
- Where
- China
- Volunteers
- 890 people
- Sponsor
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Total Knee Arthroplasty
Vancomycin in TKAs
Periprosthetic joint infection (PJI) is a national health crisis and leads to very poor outcomes for patients undergoing elective joint replacement.
- Trial name
- NCT07282782
- Testing
- Vancomycin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego